Gabius, H. J. Animal lectins. Eur. J. Biochem. 243, 543–576 (1997).
Sharon, N. & Lis, H. Lectins: from hemagglutinins to biological recognition molecules. A historical overview. Glycobiology 14, 53–62 (2004).
Feizi, T. Progress in deciphering the information content of the 'glycome' — a crescendo in the closing years of the millennium. Glycoconj. J. 17, 553–565 (2000).
Barondes, S. H. et al. Galectins: a family of animal β-galactoside-binding lectins. Cell 76, 597–598 (1994).
Cooper, D. N. Galectinomics: finding themes in complexity. Biochim. Biophys. Acta. 1572, 209–231 (2002). A comprehensive review of the emerging themes of the complex field of galectins, in particular the structural features of galectins in diverse animal species.
Leffler, H., Carlsson, S., Hedlund, M., Qian, Y. & Poirier, F. Introduction to galectins. Glycoconj. J. 19, 433–440 (2004). A succinct overview of many aspects of the galectin field.
Houzelstein, D. et al. Phylogenetic analysis of the vertebrate galectin family. Mol. Biol. Evol 21, 1177–1187 (2004).
Rini, J. M. & Lobsanov, Y. D. New animal lectin structures. Curr. Opin. Struct. Biol. 9, 578–584 (1999).
Hirabayashi, J. et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim. Biophys. Acta. 1572, 232–254 (2002).
Ahmad, N. et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J. Biol. Chem 279, 10841–10847 (2004).
Brewer, C. F., Miceli, M. C. & Baum, L. G. Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr. Opin. Struct. Biol. 12, 616–623 (2002).
Cooper, D. N. W. & Barondes, S. H. Evidence for export of a muscle lectin from cytosol to extracellular matrix and for a novel secretory mechanism. J. Cell Biol. 110, 1681–1691 (1990).
Hughes, R. C. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim. Biophys. Acta. 1473, 172–185 (1999).
Liu, F. T., Patterson, R. J. & Wang, J. L. Intracellular functions of galectins. Biochim. Biophys. Acta. 1572, 263–273 (2002).
Chiariotti, L., Salvatore, P., Frunzio, R. & Bruni, C. B. Galectin genes: regulation of expression. Glycoconj. J. 19, 441–449 (2002).
Danguy, A., Camby, I. & Kiss, R. Galectins and cancer. Biochim. Biophys. Acta. 1572, 285–293 (2002).
van den Brule, F., Califice, S. & Castronovo, V. Expression of galectins in cancer: a critical review. Glycoconj. J. 19, 537–542 (2004).
Lahm, H. et al. Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj. J. 20, 227–238 (2004).
Huflejt, M. E. & Leffler, H. Galectin-4 in normal tissues and cancer. Glycoconj. J. 20, 557–563 (2004).
Bidon-Wagner, N. & Le Pennec, J. P. Human galectin-8 isoforms and cancer. Glycoconj. J. 19, 557–563 (2004).
Oka, N., Takenaka, Y. & Raz, A. Galectins and urological cancer. J. Cell. Biochem. 91, 118–124 (2004).
Hughes, R. C. Galectins as modulators of cell adhesion. Biochimie 83, 667–676 (2001).
Hikita, C. et al. Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin 3. J. Cell Biol. 151, 1235–1146 (2001).
Ochieng, J., Warfieldl, P., Green-Jarvis, B. & Fentie, I. Galectin-3 regulates the adhesive interaction between breast carcinoma cells and elastin. J. Cell. Biochem. 75, 505–514 (1999).
Davidson, P. J. et al. Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 12, 329–337 (2002).
Dagher, S. F., Wang, J. L. & Patterson, R. J. Identification of galectin-3 as a factor in pre-mRNA splicing. Proc. Natl Acad. Sci. USA 92, 1213–1217 (1995).
Vyakarnam, A., Dagher, S. F., Wang, J. L. & Patterson, R. J. Evidence for a role for galectin-1 in pre-mRNA splicing. Mol. Cell Biol. 17, 4730–4737 (1997).
Wang, J. L., Gray, R. M., Haudek, K. C. & Patterson, R. J. Nucleocytoplasmic lectins. Biochim. Biophys. Acta. 1673, 75–93 (2004). A review that focuses on lectins inside the cell and their participation in fundamental intracellular processes such as pre-mRNA splicing — a process that is independent of the carbohydrate-binding properties of galectins.
Yamaoka, K. et al. Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J. Neurosci. Res. 59, 722–730 (2000).
Honjo, Y., Nangia-Makker, P., Inohara, H. & Raz, A. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin. Cancer Res. 7, 661–668 (2001).
Yoshii, T. et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int. J. Oncol. 18, 787–792 (2001).
Takenaka, Y et al. Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett. 195, 111–119 (2003).
Paz, A., Haklai, R., Elad-Sfadia, G., Ballan, E. & Kloog, Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 20, 7486–7493 (2001). This paper demonstrates that galectin-1 binds oncogenic Ras, helping it to anchor to the plasma membrane and mediate cell transformation.
Elad-Sfadia, G., Haklai, R., Ballan, E. & Kloog, Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J. Biol. Chem. 279, 34922–34930 (2004).
Elad-Sfadia, G., Haklai, R., Ballan, E., Gabius, H. J. & Kloog Y. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J. Biol. Chem. 277, 37169–37175 (2002).
Hoyer, K. K. et al. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am. J. Pathol. 164, 893–902 (2004).
Takenaka, Y. et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol. Cell. Biol. 24, 4395–4406 (2004).
Choi, J. H., Chun, K. H., Raz, A. & Lotan, R. Inhibition of N-(4-hydroxyphenyl)retinamide-induced apoptosis in breast cancer cells by galectin-3. Cancer Biol. Ther. 3, 447–452 (2004).
Yu, F., Finley, R. L. Jr, Raz, A. & Kim, H. R. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J. Biol. Chem. 277, 15819–15827 (2002).
Matarrese, P. et al. Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett. 473, 311–315 (2000).
Huflejt, M. E., Turck, C. W., Lindstedt, R., Barondes, S. H. & Leffler, H. L-29, a soluble lactose-binding lectin, is phosphorylated on serine 6 and serine 12 in vivo and by casein kinase I. J. Biol. Chem. 268, 26712–26718 (1993).
Cowles, E. A., Agrwal, N., Anderson, R. L. & Wang, J. L. Carbohydrate-binding protein 35. Isoelectric points of the polypeptide and a phosphorylated derivative. J. Biol. Chem. 265, 17706–17712 (1990).
Yoshii, T. et al. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J. Biol. Chem. 277, 6852–6857 (2002).
Yang, R. -Y., Hsu, D. K. & Liu, F. -T. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc. Natl Acad. Sci. USA 93, 6737–6742 (1996). The first paper to demonstrate the anti-apoptotic function of galectin-3.
Akahani, S., Nangia-Makker, P., Inohara, H., Kim, H. R. & Raz, A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 57, 5272–5276 (1997).
Califice, S., Castronovo, V., Bracke, M. & van Den Brule, F. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23, 7527–7536 (2004).
Yang, R. Y. & Liu, F. -T. Galectins in cell growth and apoptosis. Cell. Mol. Life Sci. 60, 267–276 (2003).
Bernerd, F., Sarasin, A. & Magnaldo, T. Galectin-7 overexpression is associated with the apoptotic process in UVB-induced sunburn keratinocytes. Proc. Natl Acad. Sci. USA 96, 11329–11334 (1999).
Kuwabara, I. et al. Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J. Biol. Chem 277, 3487–3497 (2002).
Hotta, K. et al. Galectin-12, an adipose-expressed galectin-like molecule possessing apoptosis-inducing activity. J. Biol. Chem 276, 34089–34097 (2001).
Hsu, D. K. et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am. J. Pathol. 156, 1073–1083 (2000).
Okada, H. & Mak, T. W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nature Rev. Cancer 4, 592–603 (2004).
Wells, V., Davies, D. & Mallucci, L. Cell cycle arrest and induction of apoptosis by β-galactoside binding protein (β GBP) in human mammary cancer cells. A potential new approach to cancer control. Eur. J. Cancer 35, 978–983 (1999).
Kopitz, J. et al. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J. Biol. Chem. 276, 35917–35923 (2001).
Kopitz, J. et al. Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells. Oncogene 22, 6277–6288 (2003).
van den Brüle, F. A. et al. Antisense galectin-3 alters thymidine incorporation in human MDA-MB435 breast cancer cells. Int. J. Oncol. 11, 261–264 (1997).
Ellerhorst, J. A., Stephens, L. C., Nguyen, T. & Xu, X. C. Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP. Prostate 50, 64–70 (2002).
Paron, I. et al. Nuclear localization of galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem. Biophys. Res. Commun. 302, 545–553 (2003).
Ueda, S., Kuwabara, I. & Liu, F. -T. Suppression of tumor growth by galectin-7 gene transfer. Cancer Res. 64, 5672–5676 (2004).
Kim, H. R., Lin, H. M., Biliran, H. & Raz, A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 59, 4148–4154 (1999).
Lin, H. M., Pestell, R. G., Raz, A. & Kim, H. R. Galectin-3 enhances cyclin D1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 21, 8001–8010 (2002).
Shimura, T. et al. Galectin-3, a novel binding partner of β-catenin. Cancer Res. 64, 6363–6367 (2004).
Yang, R. Y., Hsu, D. K., Yu, L., Ni, J. & Liu, F. -T. Cell cycle regulation by galectin-12, a member of the galectin superfamily. J. Biol. Chem. 276, 20252–20260 (2001).
Hood, J. D. & Cheresh, D. A. Role of integrins in cell invasion and migration. Nature Rev. Cancer 2, 91–100 (2002).
Ochieng, J., Furtak, V. & Lukyanov, P. Extracellular functions of galectin-3. Glycoconj. J. 19, 527–535 (2004).
Kuwabara, I., Sano, H. & Liu, F. T. Functions of galectins in cell adhesion and chemotaxis. Methods Enzymol. 363, 532–552 (2003).
Levy, Y. et al. Galectin-8 functions as a matricellular modulator of cell adhesion. J. Biol. Chem. 276, 31285–31295 (2001).
van den Brüle, F. et al. Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab. Invest. 83, 377–386 (2003).
Ellerhorst, J., Nguyen, T., Cooper, D. N., Lotan, D. & Lotan, R. Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype. Int. J. Oncol. 14, 217–224 (1999).
Glinsky, V. V. et al. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 63, 3805–3811 (2003)
Khaldoyanidi, S. K. et al. MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J. Biol. Chem. 278, 4127–4134 (2003).
Gu, M., Wang, W., Song, W. K., Cooper, D. N. W. & Kaufman, S. J. Selective modulation of the interaction of α7β1 integrin with fibronectin and laminin by L-14 lectin during skeletal muscle differentiation. J. Cell Sci. 107, 175–181 (1994).
Ochieng, J., Leite-Browning, M. L. & Warfield, P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem. Biophys. Res. Commun. 246, 788–791 (1998).
Nishi, N. et al. Galectin-8 modulates neutrophil function via interaction with integrin alpha M. Glycobiology 13, 755–763 (2003).
Mataresse, P. et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int. J. Cancer 85, 545–554 (2000).
Le Marer, N. & Hughes, R. C. Effects of the carbohydrate-binding protein galectin-3 on the invasiveness of human breast carcinoma cells. J. Cell Physiol. 168, 51–58 (1996).
Hittelet, A. et al. Upregulation of galectins-1 and-3 in human colon cancer and their role in regulating cell migration. Int. J. Cancer 103, 370–379 (2003).
O'Driscoll, L. et al. Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Res. 22, 3117–3125 (2002).
Camby, I. et al. Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J. Neuropathol. Exp. Neurol. 61, 585–596 (2002).
Nagy, N. et al. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 50, 392–401 (2002).
Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15–18 (2002).
Nangia-Makker, P. et al. Galectin-3 induces endothetial cell morphogenesis and angiogenesis. Am. J. Pathol. 156, 899–909 (2000). This paper demonstrates the proangiogenic activity of galectin-3.
Furtak, V., Hatcher, F. & Ochieng, J. Galectin-3 mediates the endocytosis of β-1 integrins by breast carcinoma cells. Biochem. Biophys. Res. Commun. 289, 845–850 (2001).
Partridge, E. A. et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306, 120–124 (2004).
Ochieng, J., Green, B., Evans, S., James, O. & Warfield, P. Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochim. Biophys. Acta. 1379, 97–106 (1998).
Bresalier, R. S. et al. Metastasis of human colon cancer is altered by modifying expression of the β-galactoside-binding protein galectin 3. Gastroenterology 115, 287–296 (1998).
Takenaka, Y., Fukumori, T. & Raz, A. Galectin-3 and metastasis. Glycoconj. J. 19, 543–549 (2004).
Inufusa, H. et al. Role of galectin-3 in adenocarcinoma liver metastasis. Int. J. Oncol. 19, 913–919 (2001).
Song, Y. K., Billiar, T. R. & Lee, Y. J. Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am. J. Pathol. 160, 1069–1075 (2002).
Luo, J. -L., Maeda, S., Hsu, L. -C., Yagita, H. & Karin, M. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 6, 297–305 (2004).
Balkwill, F. Cancer and the chemokine network. Nature Rev. Cancer 4, 540–550 (2004).
Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nature Rev. Cancer 4, 71–78 (2004).
Gabrilovich, D. & Pisarev, V. Tumor escape from immune response: mechanisms and targets of activity. Curr. Drug Targets 4, 525–536 (2003).
Pardoll, D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807–839 (2003).
Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137–148 (2004).
Rabinovich, G. A., Toscano, M. A., Ilarregui, J. M. & Rubinstein, N. Shedding light on the immunomodulatory properties of galectins: novel regulators of innate and adaptive immune responses. Glycoconj. J. 19, 565–573 (2004).
Liu, F. -T. Galectins: a new family of regulators of inflammation. Clin. Immunol. 97, 79–88 (2000).
Vasta, G. R., Quesenberry, M., Ahmed, H. & O'Leary, N. C-type lectins and galectins mediate innate and adaptive immune functions: their roles in the complement activation pathway. Dev. Comp. Immunol. 23, 401–420 (1999).
Sato, S. & Nieminen, J. Seeing strangers or announcing 'danger': galectin-3 in two models of innate immunity. Glycoconj. J. 19, 583–591 (2004).
Young, A. R. & Meeusen, E. N. Galectins in parasite infection and allergic inflammation. Glycoconj. J. 19, 601–606 (2004).
Rabinovich, G. A. et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 23, 313–320 (2002). A comprehensive review on the role of galectins in the inflammatory response
Chung, C. D., Patel, V. P., Moran, M., Lewis, L. A. & Miceli, M. C. Galectin-1 induces partial TCR ζ-chain phosphorylation and antagonizes processive TCR signal transduction. J. Immunol. 165, 3722–3729 (2000).
Blaser, C. et al. β-galactoside binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur. J. Immunol 28, 2311–2319 (1998).
Perillo, N. L., Pace, K. E., Seilhamer, J. J. & Baum, L. G. Apoptosis of T cells mediated by galectin-1. Nature 378, 736–739 (1995). The first paper demonstrating the ability of galectin-1 to induce apoptosis in T cells.
Rabinovich, G. A. et al. Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells: biochemical and functional characterization. J. Immunol. 160, 4831–4840 (1998).
Rabinovich, G. A. et al. Induction of allogenic T-cell hyporesponsiveness by galectin-1-mediated apoptotic and non-apoptotic mechanisms. Cell Death Differ. 9, 661–670 (2002).
He, J. & Baum, L. G. Presentation of galectin-1 by extracellular matrix triggers T cell death. J. Biol. Chem. 279, 4705–4712 (2004).
Rabinovich, G. A. et al. Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology 97, 100–106 (1999)
Rabinovich, G. A. et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J. Exp. Med. 190, 385–397 (1999).
Santucci, L. et al. Galectin-1 suppresses experimental colitis in mice. Gastroenterology 124, 1381–1394 (2003).
Baum, L. G. et al. Amelioration of graft versus host disease by galectin-1. Clin. Immunol. 109, 295–307 (2003).
Galvan, M., Tsuboi, S., Fukuda, M. & Baum, L. G. Expression of a specific glycosyltransferase enzyme regulates T cell death mediated by galectin-1. J. Biol. Chem., 275, 16730–16737 (2000).
Pace, K. E., Lee, C., Stewart, P. L. & Baum, L. G. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J. Immunol. 163, 3801–3811 (1999).
Rabinovich, G. A. et al. Molecular mechanisms implicated in galectin-1-induced apoptosis: activation of the AP-1 transcription factor and downregulation of Bcl-2. Cell Death Differ. 7, 747–753 (2000)
Walzel, H., Blach, M., Hirabayashi, J., Kasai, K. & Brock, J. Involvement of CD2 and CD3 in galectin-1 induced signaling in human Jurkat T-cells. Glycobiology 10, 131–140 (2000).
Hahn, H. P. et al. Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death Differ. 11, 1277–1286 (2004).
Dias-Baruffi, M. et al. Dimeric galectin-1 induces surface exposure of phosphatidylserine and phagocytic recognition of leukocytes without inducing apoptosis. J. Biol. Chem. 278, 41282–41293 (2003).
Rubinstein, N. et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 5, 241–251 (2004). Demonstration that inhibition of galectin-1 gene expression in tumour cells results in heightened T-cell mediated tumour rejection, thereby validating galectin-1 as a target for cancer therapy in an animal model.
Rabinovich, G. A., Sotomayor, C. E., Riera, C. M., Bianco, I. & Correa, S. G. Evidence of a role for galectin-1 in acute inflammation. Eur. J. Immunol 30, 1331–1339 (2000).
La, M. et al. A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation. Am. J. Pathol. 163, 1505–1515 (2003).
Sano, H. et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J. Immunol. 165, 2156–2164 (2000).
Colnot, C. et al. Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology 94, 290–296 (1998).
Zuberi, R. I. et al. Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am. J. Pathol. (In the press).
Fukumori, T. et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 63, 8302–8311 (2003).
Demetriou, M., Granovsky, M., Quaggin, S. & Dennis, J. W. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409, 733–779 (2001).
Cortegano, I. et al. Galectin-3 down-regulates IL-5 gene expression on different cell types. J. Immunol. 161, 385–389 (1998).
Acosta-Rodríguez, E. V. et al. Galectin-3 mediates IL-4-induced survival and differentiation of B cells: functional cross-talk and implications during Trypanosoma cruzi infection. J. Immunol. 172, 493–502 (2004).
Sturm, A. et al. Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J. Immunol. 173, 3825–3837 (2004).
Ozaki, K. et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-α secretion in vitro. Nature 429, 72–75 (2004).
Hokama, A. et al. Induced reactivity of intestinal CD4+ T cells with an epithelial cell lectin, galectin-4, contributes to exacerbation of intestinal inflammation. Immunity 20, 681–693 (2004).
Wada, J., Ota, K., Kumar, A., Wallner, E. I. & Kanwar, Y. S. Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin. J. Clin. Invest. 99, 2452–2461 (1997).
Kashio, Y, et al. Galectin-9 induces apoptosis through the calcium–calpain–caspase-1 pathway. J. Immunol. 170, 3631–3636 (2003).
Matsumoto, R. et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J. Biol. Chem 273, 16976–16984 (1998).
Poirier, F. Roles of galectins in vivo. Biochem. Soc. Symp. 69, 95–103 (2002).
Lahm, H. et al. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J. Cancer Res. Clin. Oncol. 127, 375–386 (2001)
John, C. M., Leffler, H., Kahl-Knutsson, B., Svensson, I. & Jarvis, G. A. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin. Cancer Res. 9, 2374–2383 (2003).
Zou, J., Glinsky, V. V., Landon, L. A., Matthews, L. & Deutscher, S. L. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis–associated cancer cell adhesion. Carcinogenesis (In the press).
Sorme, P., Qian, Y., Nyholm, P. G., Leffler, H. & Nilsson, U. J. Low micromolar inhibitors of galectin-3 based on 3'-derivatization of N-acetyllactosamine. Chembiochem 3, 183–189 (2002).
Andre, S. et al. Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to glycoproteins, lactose maxiclusters, and cell surface glycoconjugates. Chembiochem 2, 822–830 (2001).
Lu, Y. Lotan, D. & Lotan, R. Differential regulation of constitutive and retinoic acid-induced galectin-1 gene transcription in murine embryonal carcinoma and myoblastic cells. Biochim. Biophys. Acta. 1491, 13–19 (2000).
Rabinovich, G. A. et al. The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 expression. Cancer Immunol. Immunother. 50, 597–603 (2002).
Trapani, J. A. Tumor-mediated apoptosis of cancer-specific T lymphocytes — reversing the 'kiss of death'? Cancer Cell 2, 169–171 (2002).
Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med. 8, 793–800 (2002).
Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Med. 9, 1269–1274 (2003).
Yu, H. & Jove, R. The STATs of cancer — new molecular targets come of age. Nature Rev. Cancer 4, 97–105 (2004).
Almkvist, J. & Karlsson A. Galectins as inflammatory mediators. Glycoconj. J. 19, 575–581 (2004).